# A Long-Term Study in Schizophrenia

> **NCT01487083** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 282 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Pomaglumetad methionil

## Key facts

- **NCT ID:** NCT01487083
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 282 (ESTIMATED)
- **Why stopped:** The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.
- **Last updated:** 2013-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01487083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01487083, "A Long-Term Study in Schizophrenia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01487083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*